Clinical Trials Logo

CCND3 Positive clinical trials

View clinical trials related to CCND3 Positive.

Filter by:
  • None
  • Page 1

NCT ID: NCT01880567 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Start date: July 15, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ibrutinib and rituximab work in treating patients with mantle cell lymphoma that has come back or has not responded to treatment or older patients with newly diagnosed mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them. Giving ibrutinib and rituximab may be an effective treatment for mantle cell lymphoma.